fangdisun· @fangdisun · X·· 4 days agoScore60
Body
#ESMO26 starts in less than a week! My summary and comments on notable #HNcancer studies, with several that help contextualize ongoing Ph3 trials in 1L R/M setting. ‼️ None immediately practice-changing in the US, but hope to see more data in the next 1-2 years. @OncBrothers @OncoAlert @myESMO @OncLive
Heat 10 · 6 likes · 0 replies · 4 reposts
Conference abstracts
NCT04943445NCT04943445matched by - **标题 / Title：** Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
- **标题 / Title：** Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx CancersRead the abstract →NCT06295731NCT06295731matched by - **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
- **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCRead the abstract →NCT06385080NCT06385080matched by - **标题 / Title：** A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- **标题 / Title：** A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck CancerRead the abstract →NCT06437522NCT06437522matched by - **标题 / Title：** A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
- **标题 / Title：** A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRead the abstract →NCT06629597NCT06629597matched by - **标题 / Title：** A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)
- **标题 / Title：** A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)Read the abstract →NCT07276399NCT07276399matched by - **标题 / Title：** A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- **标题 / Title：** A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerRead the abstract →Source: fangdisun · x.com